Table 4

ORs with 95% CIs of developing endometrial cancer according to quartiles of serum levels of specific PCB congeners^a

Congener	Model^b	OR (95% CI)						P for trend^c
Congener	Model^b			Quartile 1	Quartile 2	Quartile 3	Quartile 4	P for trend^c
CB 105	Age-adjusted	1.0	1.4 (0.7–2.6)	1.2 (0.6–2.4)	1.2 (0.6–2.3)	0.69
	Multivariate	1.0	1.2 (0.6–2.3)	1.0 (0.5–1.8)	0.8 (0.4–1.6)	0.42
CB 118	Age-adjusted	1.0	1.7 (0.9–3.3)	1.6 (0.8–3.1)	1.9 (1.0–3.7)	0.11
	Multivariate	1.0	0.6 (0.8–3.0)	1.2 (0.6–2.4)	1.4 (0.7–2.8)	0.58
CB 138	Age-adjusted	1.0	0.9 (0.5–1.8)	1.2 (0.7–2.2)	1.0 (0.6–1.9)	0.74
	Multivariate	1.0	0.8 (0.4–1.6)	1.2 (0.6–2.2)	0.9 (0.5–1.7)	0.95
CB 153	Age-adjusted	1.0	0.9 (0.5–1.7)	1.1 (0.6–2.0)	0.8 (0.4–1.4)	0.58
	Multivariate	1.0	0.9 (0.5–1.7)	1.2 (0.6–2.2)	0.9 (0.5–1.7)	0.94
CB 156	Age-adjusted	1.0	1.4 (0.8–2.5)	1.1 (0.6–2.0)	0.7 (0.4–1.3)	0.18
	Multivariate	1.0	1.6 (0.8–2.9)	1.4 (0.7–2.6)	1.0 (0.5–2.0)	0.90
CB 167	Age-adjusted	1.0	2.2 (1.1–4.2)	1.6 (0.8–3.2)	2.0 (1.0–4.1)	0.19
	Multivariate	1.0	2.0 (1.0–3.9)	1.4 (0.7–2.9)	1.9 (0.9–3.9)	0.24
CB 180	Age-adjusted	1.0	0.9 (0.5–1.6)	0.8 (0.5–1.5)	0.7 (0.4–1.4)	0.32
	Multivariate	1.0	1.1 (0.6–2.0)	1.1 (0.6–2.2)	1.2 (0.6–2.2)	0.67

^a Median values for quartile 1 (cases/controls); quartile 4 (cases/controls), in ng/g lipid: CB 105, 1/1; 11.5/10.7; CB 118, 25.2/20.3; 73.4/70.9; CB 138, 67/59.1; 154/165; CB 153, 157/143; 342.5/351; CB 156, 12.9/12; 28.3/27.5; CB 167, 5/4.6; 14.7/15; CB 180, 108.5/103; 224.5/227.
^b Multivariate adjusted for age and BMI.
^c Tests for trend were performed by assigning consecutive integers to levels of categorized variables.